Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- 1 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (9), 2616-2624
- https://doi.org/10.1158/1535-7163.mct-09-0483
Abstract
Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) was highly and universally expressed on myeloma cells while having restricted expression in normal tissues. Elotuzumab (formerly known as HuLuc63), a humanized mAb targeting CS1, is currently in a phase I clinical trial in relapsed/refractory myeloma. In this report we investigated whether the activity of elotuzumab could be enhanced by bortezomib, a reversible proteasome inhibitor with significant activity in myeloma. We first showed that elotuzumab could induce patient-derived myeloma cell killing within the bone marrow microenvironment using a SCID-hu mouse model. We next showed that CS1 gene and cell surface protein expression persisted on myeloma patient-derived plasma cells collected after bortezomib administration. In vitro bortezomib pretreatment of myeloma targets significantly enhanced elotuzumab-mediated antibody-dependent cell-mediated cytotoxicity, both for OPM2 myeloma cells using natural killer or peripheral blood mononuclear cells from healthy donors and for primary myeloma cells using autologous natural killer effector cells. In an OPM2 myeloma xenograft model, elotuzumab in combination with bortezomib exhibited significantly enhanced in vivo antitumor activity. These findings provide the rationale for a clinical trial combining elotuzumab and bortezomib, which will test the hypothesis that combining both drugs would result in enhanced immune lysis of myeloma by elotuzumab and direct targeting of myeloma by bortezomib. [Mol Cancer Ther 2009;8(9):2616–24]Keywords
Other Versions
This publication has 32 references indexed in Scilit:
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood, 2008
- Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myelomaBlood, 2008
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3British Journal of Haematology, 2007
- Rituximab in CD20 positive multiple myelomaLeukemia, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myelomaLeukemia & Lymphoma, 2006
- Novel targeted drugs for the treatment of multiple myeloma: from bench to bedsideLeukemia, 2005
- RETRACTED: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical ImplicationsCancer Research, 2004
- PHASE I STUDY OF SAFETY AND PHARMACOKINETICS OF A HUMAN ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODY IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTSTransplantation, 1991